TCT 2022: Impella Enables Complete Revascularization, Improved Quality of Life and Native Heart Recovery
Abiomed (Nasdaq: ABMD) will highlight how Impella heart pumps help heart teams achieve more complete high-risk revascularization and heart recovery in the catheterization lab and operating room at the Transcatheter Cardiovascular Therapeutics (TCT) 2022 Conference, held in Boston from September 16 to 19.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220913005521/en/
Impella 5.5 with SmartAssist delivers full cardiac support with maximum unloading, allowing the heart to rest and recover. (Graphic: Business Wire)
During the conference, physician-researchers will present clinical data demonstrating Impella leads to higher survival rates for cardiogenic shock patients and quality of life improvements for heart failure patients. Additional presentations and live cases will describe how Impella innovation and best practices have advanced safety and ease-of-use. Attendees can also receive hands-on Impella training and learn about future Impella technology.
Clinical Data Presentations:
Impella will be featured in presentations on topics that include a new analysis of data from the STEMI-DTU pilot randomized controlled trial and new data on cardiogenic shock and myocarditis outcomes from the J-PVAD registry in Japan. The J-PVAD registry is overseen by 10 Japanese professional societies, including the Japanese Circulation Society.
Abiomed’s preCARDIA technology to treat acute decompensated heart failure (ADHF) will be featured in two presentations that provide data showing preCARDIA reduces stressed blood volume and improves urine sodium excretion in ADHF patients.
Additionally, Abiomed will host two symposia with physician-researchers discussing the benefits of Impella as a therapy for patients in cardiogenic shock and Impella-supported high-risk PCI. They are:
- From Shock Spiral to Survival: Achieving Heart Recovery in Cardiogenic Shock – This in-person symposium takes place on Saturday, September 17, from 12:45–1:45 pm EDT in the TCT Presentation Theatre. Navin K. Kapur, MD, Tufts Medical Center, Boston; Katherine Kunkel, MD, Piedmont Heart Institute, Atlanta; Junya Ako, MD, Kitasato University Hospital, Tokyo; and Jay Giri, MD, MPH, Penn Medicine, Philadelphia, will present on best practices for Impella use to improve cardiogenic shock survival. A panel discussion will take place that will also include William O’Neill, MD and Mir Babar Basir, DO, from Henry Ford Hospital, Detroit.
- The CAD’s Out of the Bag: Achieving Heart Recovery in High-Risk Revascularization – This symposium is in-person and will be live streamed from the TCT World Connect Theatre on Sunday, September 18, from 12:30–1:30 pm EDT. Jonathan Hill, MD, Royal Brompton and Harefield Hospital, London; and Kate Kearney, MD, University of Washington, Seattle, will discuss clinical trials and best practices for Impella-supported high-risk PCI. Additionally, Navin K. Kapur, MD, Tufts Medical Center, Boston, will discuss ventricular unloading and what can be learned from the STEMI-DTU randomized controlled trial. A panel discussion will take place that will also include Gregg Stone, MD, Mount Sinai Health System, New York; Amir Kaki, MD, Ascension St. John Hospital, Detroit; and Cindy Grines, MD, Northside Hospital, Atlanta.
A detailed agenda for each symposium is available at this link on the TCT website.
Technology and Training:
Physicians attending the conference can receive hands-on Impella best practice training in the TCT Training Pavilion on topics such as access and closure, Impella RP with SmartAssist insertion and advanced Impella management. The esteemed faculty teaching these courses are Rajiv Tayal, MD, Valley Health System, Ridgewood, NJ; Robert Salazar, MD, Memorial Hermann, Houston; and Dan Burkhoff, MD, PhD, Cardiovascular Research Foundation. A detailed agenda for each training is available at this link on the TCT website.
Conference attendees are invited to visit the Abiomed booth, in the TCT Exhibit Hall. Abiomed’s booth will feature the latest Impella technology, including Impella 5.5 with SmartAssist and Impella RP with SmartAssist. Future pipeline technology will be available to preview, including Impella ECP, Impella RP Flex, Impella BTR and preCARDIA. Additionally, advanced Impella trainers will be available to answer questions about Impella’s new heparin-free purge, provide a hands-on experience with the Impella simulator and guide attendees through Abiomed’s new virtual reality training technology.
Live Daily Recap Program:
Abiomed’s TCT daily recap program will broadcast live from 6:00–6:30 pm EDT on Saturday, September 17 through Monday, September 19. The program will summarize the day’s news from TCT. It will be hosted by Abiomed’s chief medical officer, Chuck Simonton, MD, and Abiomed’s vice president for professional education and medical communication, Seth Bilazarian, MD. To watch live, log on to www.heartrecovery.com.
ABOUT IMPELLA HEART PUMPS
The Impella 2.5® and Impella CP® with SmartAssist® are U.S. FDA approved to treat certain advanced heart failure patients undergoing elective and urgent percutaneous coronary interventions (PCI), such as stenting or balloon angioplasty, to reopen blocked coronary arteries.
Impella 2.5, Impella CP®, Impella CP with SmartAssist, Impella 5.0®, Impella LD® and Impella 5.5® with SmartAssist® are U.S. FDA approved to treat heart attack or cardiomyopathy patients in cardiogenic shock and have the unique ability to enable native heart recovery, allowing patients to return home with their own heart.
Impella RP® and Impella RP® with SmartAssist are U.S. FDA approved to treat right heart failure or decompensation following left ventricular assist device implantation, myocardial infarction, heart transplant or open-heart surgery.
ABOUT ABIOMED
Based in Danvers, Massachusetts, USA, Abiomed, Inc., is a leading provider of medical technology that provides circulatory support and oxygenation. Our products are designed to enable the heart to rest by improving blood flow and/or provide sufficient oxygenation to those in respiratory failure. For additional information, please visit: http://www.abiomed.com.
FORWARD-LOOKING STATEMENTS
Any forward-looking statements are subject to risks and uncertainties such as those described in Abiomed's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220913005521/en/
Contact information
Media Contact:
Jenny Leary
Associate Director, U.S. Communications
+1 (978) 882-8491
jleary@abiomed.com
Investor Contact:
Todd Trapp
Executive Vice President and Chief Financial Officer
+1 (978) 646-1680
ttrapp@abiomed.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Adversaries Continue Cyberattack Onslaught with Greater Precision and Innovative Attack Methods according to 1H2022 NETSCOUT DDoS Threat Intelligence Report27.9.2022 13:05:00 EEST | Press release
NETSCOUT SYSTEMS, INC. (NASDAQ: NTCT) today announced findings from its 1H2022 DDoS Threat Intelligence Report. The findings demonstrate how sophisticated cybercriminals have become at bypassing defenses with new DDoS attack vectors and successful methodologies. "By constantly innovating and adapting, attackers are designing new, more effective DDoS attack vectors or doubling down on existing effective methodologies," said Richard Hummel, threat intelligence lead, NETSCOUT. "In the first half of 2022, attackers conducted more pre-attack reconnaissance, exercised a new attack vector called TP240 PhoneHome, created a tsunami of TCP flooding attacks, and rapidly expanded high-powered botnets to plague network-connected resources. In addition, bad actors have openly embraced online aggression with high-profile DDoS attack campaigns related to geopolitical unrest, which have had global implications." Deployed in most of the world's ISPs, large data centers, and government and enterprise net
EVER Pharma Launches the User-friendly D-mine® Pump Generated Report “DATA-mine®” to Enhance the Therapy Management of Parkinson’s Patients on Apomorphine27.9.2022 12:30:00 EEST | Press release
After successfully launching the D-mine ® Pump, a micro infusion device designed to provide precise continuous subcutaneous drug delivery for PD patients, the product family has been extended to include a comprehensive data history readout. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220915005029/en/ The user-friendly DATA-mine® REPORT (Graphic: Business Wire) EVER Pharma, a specialist in neurology and specialty pharmaceuticals, offers a complete therapy package for PD patients with Dacepton® (Dopaceptin®, Apomorphine hydrochloride), D-mine® Pump, D-mine ® Pen and now the DATA-mine® REPORT, a tool to read out the data of the D-mine ® Pump. Through this tool the D-mine ® Pump history file can be easily transformed into a handy report in PDF format, on Windows or macOS devices allowing Healthcare Professionals to navigate through the various parameters of the infusion therapy like dosing, flow rates, and time settings in ea
Entrust Your Home's Hygiene to BioBellinda’s New Probiotic Formula27.9.2022 11:48:00 EEST | Press release
As the pandemic wore on, our hygiene sensitivity increased the time spent cleaning our homes, leading to ever greater use of cleaning materials that contain heavy chemical substances such as bleach and disinfectants. Research reveals that such products can destroy useful probiotics, or beneficial organisms, alongside bacteria, creating clean but unnaturally sterile living spaces. UK research suggests that cleaning products with probiotic properties reduce germs and viruses by up to 80%. Probiotic cleaning products prevent the proliferation of harmful bacteria, mould and viruses by 60%, while reducing infectious diseases by 52%. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220927005589/en/ Entrust your home's hygiene to BioBellinda’s new probiotic formula (Graphic: Business Wire) Explaining that our homes have both harmful and beneficial microorganisms just like the human body, BioBellinda R&D Specialist, Microbiologist Küb
Chicago O’Hare Replaces London Heathrow As No. 1 Most Connected Airport27.9.2022 11:00:00 EEST | Press release
OAG, the world’s leading data platform for the global travel industry, today released Megahubs 2022, the Top 50 most internationally connected airports in the world. Last updated in 2019, Megahubs provides fresh insight into how ongoing travel disruptions are affecting global connectivity. While London Heathrow (LHR) maintained its first-place ranking among European hubs, its global ranking dropped from #1 in 2019 to #22 this year. Paris Charles de Gaulle Airport (CDG) and Frankfurt Airport (FRA) experienced similar drops, falling out of the top 10 to #27 and #30. U.S. airports dominated the global Megahubs, with Chicago O’Hare (ORD; #1), Dallas/Fort Worth International Airport (DFW; #2) and Atlanta Hartsfield-Jackson International Airport (ATL; #3) finishing as the top three most connected airports in the world. Mexico City Juarez International Airport (MEX) is the highest ranked non-U.S. Megahub ranking #8, up 7 spots from its #15 ranking in 2019. “The global market has yet to fully
Marki Microwave Expands Millimeter Wave Portfolio with Series of High Performance Integrated Drive Mixers27.9.2022 09:50:00 EEST | Press release
European Microwave Week – Marki Microwave®, innovator in the radio frequency and microwave industry for over 30 years, today announced the expansion of its millimeter wave (mmWave) portfolio with a series of leading-edge mixers featuring integrated local oscillator (LO) drivers. Ideal for space constrained applications requiring wide bandwidths and operation at mmWave frequencies, the integrated drive mixers reduce size, weight, power and cost (SWaP-C) while simplifying overall integration of the LO path for ease of use and optimized performance. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220926005833/en/ Marki Microwave's versatile, broadband double balanced mixers feature an integrated LO driver amplifier, which allows for operation with LO powers as low as -6 dBm. (Graphic: Business Wire) “For customers needing to realize the best performance in a small footprint with reduced design effort, our latest integrated drive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom